Skip Navigation
Skip to contents

Cancer Res Treat : Cancer Research and Treatment

OPEN ACCESS

Search

Page Path
HOME > Search
3 "Dong Wang"
Filter
Filter
Article category
Keywords
Publication year
Authors
Funded articles
Original Articles
Genitourinary Cancer
Neoadjuvant Chemotherapy–Guided Bladder-Sparing Treatment for Muscle-Invasive Bladder Cancer: Results of a Pilot Phase II Study
Hongzhe Shi, Wen Zhang, Xingang Bi, Dong Wang, Zejun Xiao, Youyan Guan, Kaopeng Guan, Jun Tian, Hongsong Bai, Linjun Hu, Chuanzhen Cao, Weixing Jiang, Zhilong Hu, Jin Zhang, Yan Chen, Shan Zheng, Xiaoli Feng, Changling Li, Yexiong Li, Jianhui Ma, Yueping Liu, Aiping Zhou, Jianzhong Shou
Cancer Res Treat. 2021;53(4):1156-1165.   Published online February 10, 2021
DOI: https://doi.org/10.4143/crt.2020.1356
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
Reduced quality of life after cystectomy has made bladder preservation a popular research topic for muscle-invasive bladder cancer (MIBC). Previous research has indicated significant tumor downstaging after neoadjuvant chemotherapy (NAC). However, maximal transurethral resection of bladder tumor (TURBT) was performed before NAC to define the pathology, impacting the real evaluation of NAC. This research aimed to assess real NAC efficacy without interference from TURBT and apply combined modality therapies guided by NAC efficacy.
Materials and Methods
Patients with cT2-4aN0M0 MIBC were confirmed by cystoscopic biopsy and imaging. NAC efficacy was assessed by imaging, urine cytology, and cystoscopy with multidisciplinary team discussion. Definite responders (≤ T1) underwent TURBT plus concurrent chemoradiotherapy. Incomplete responders underwent radical cystectomy or partial cystectomy if feasible. The primary endpoint was the bladder preservation rate.
Results
Fifty-nine patients were enrolled, and the median age was 63 years. Patients with cT3-4 accounted for 75%. The median number of NAC cycles was three. Definite responders were 52.5%. The complete response (CR) was 10.2%, and 59.3% of patients received bladder-sparing treatments. With a median follow-up of 44.6 months, the 3-year overall survival (OS) was 72.8%. Three-year OS and relapse-free survival were 88.4% and 60.0% in the bladder-sparing group but only 74.3% and 37.5% in the cystectomy group. The evaluations of preserved bladder function were satisfactory.
Conclusion
After stratifying MIBC patients by NAC efficacy, definite responders achieved a satisfactory bladder-sparing rate, prognosis, and bladder function. The CR rate reflected the real NAC efficacy for MIBC. This therapy is worth verifying through multicenter research.

Citations

Citations to this article as recorded by  
  • Concomitant chemotherapy in trimodal treatment of patients with muscle invasive bladder cancer: A systematic review of prospective trials
    Camille Baudelin, Paul Sargos, Derek Dinart, Christophe Hennequin, Diego Teyssonneau, Lucie Meynard, Nam-Son Vuong, Félix Lefort, Michael Baboudjian, Guilhem Roubaud
    Critical Reviews in Oncology/Hematology.2025; 205: 104557.     CrossRef
  • Does Bladder Cancer Subtype Influence Pathologic Complete Response (pCR) and Pelvic Diffusion-Weighted Magnetic Resonance Imaging (DW-MRI) Response Evaluation After Neoadjuvant Chemotherapy? Pathological Perspective
    Ji Min Kim, Euno Choi, Sun Hee Sung, Jungmin Jo, Dong-Hyeon Lee, Sanghui Park
    Clinical Genitourinary Cancer.2024; 22(2): 224.     CrossRef
  • A comparative analysis of radical cystectomy with perioperative chemotherapy, chemoradiation therapy, or systemic therapy in patients with clinically advanced node-positive bladder cancer (cN2/N3)
    Harshit Garg, Mukund Bhandari, Furkan Dursun, Michael A. Liss, Dharam Kaushik, Robert S. Svatek, Ahmed M. Mansour
    Frontiers in Oncology.2024;[Epub]     CrossRef
  • Clinical efficacy analysis of partial cystectomy and radical cystectomy in the treatment of muscle-invasive sarcomatoid carcinoma of the urinary bladder
    Jiansheng Xiao, Hua Chen, Jiaqi Ge, Tairong Liu
    Frontiers in Oncology.2024;[Epub]     CrossRef
  • Downstaging guided neoadjuvant strategy shift and bladder preservation in locally advanced bladder cancer: A case report
    Gan Du, Zhichao Jiang, Wang Qu, Jin Zhang, Shan Zheng, Yueping Liu, Aiping Zhou, Hongzhe Shi, Jianzhong Shou
    Heliyon.2024; 10(6): e27685.     CrossRef
  • Editorial: Organ-sparing surgery for genitourinary cancers
    Gongwei Long, Xingyuan Xiao, Haoran Liu, Yucong Zhang, Chunguang Yang
    Frontiers in Oncology.2024;[Epub]     CrossRef
  • News and prospects on radiotherapy for bladder cancer: Is trimodal therapy becoming the gold standard?
    Olivier Riou, Christophe Hennequin, Jonathan Khalifa, Paul Sargos
    Cancer/Radiothérapie.2024; 28(6-7): 623.     CrossRef
  • Health-related quality of life after curative treatment for muscle-invasive bladder cancer
    Elisabeth Grobet-Jeandin, Ugo Pinar, Jérôme Parra, Morgan Rouprêt, Thomas Seisen
    Nature Reviews Urology.2023; 20(5): 279.     CrossRef
  • Combined Modality Bladder-Sparing Therapy for Muscle-Invasive Bladder Cancer: How (Should) We Do It? A Narrative Review
    Artur Lemiński, Wojciech Michalski, Bartłomiej Masojć, Krystian Kaczmarek, Bartosz Małkiewicz, Jakub Kienitz, Barbara Zawisza-Lemińska, Michał Falco, Marcin Słojewski
    Journal of Clinical Medicine.2023; 12(4): 1560.     CrossRef
  • Survival after sequential neoadjuvant chemotherapy followed by trimodal treatment or radical cystectomy for muscle-invasive bladder cancer
    Pierre-Louis Reignier, Hélène Gauthier, Christophe Hennequin, Quiterie Aussedat, Evanguelos Xylinas, François Desgrandchamps, Stéphane Culine, Alexandra Masson-Lecomte, Clément Dumont
    World Journal of Urology.2023; 41(11): 3249.     CrossRef
  • Neoadjuvant chemotherapy with gemcitabine and cisplatin followed by selective bladder preservation chemoradiotherapy in muscle-invasive urothelial carcinoma of bladder
    Hyun Hwan Sung, Hana Kim, Ryul Kim, Chan Kyo Kim, Ghee Young Kwon, Won Park, Wan Song, Byong Chang Jeong, Se Hoon Park
    Investigative and Clinical Urology.2022; 63(2): 168.     CrossRef
  • Disease Management of Clinical Complete Responders to Neoadjuvant Chemotherapy of Muscle-Invasive Bladder Cancer: A Review of Literature
    Jie Wu, Rui-Yang Xie, Chuan-Zhen Cao, Bing-Qing Shang, Hong-Zhe Shi, Jian-Zhong Shou
    Frontiers in Oncology.2022;[Epub]     CrossRef
  • Contemporary Staging for Muscle-Invasive Bladder Cancer: Accuracy and Limitations
    Patrick J. Hensley, Valeria Panebianco, Eugene Pietzak, Alexander Kutikov, Raghu Vikram, Matthew D. Galsky, Shahrokh F. Shariat, Morgan Roupret, Ashish M. Kamat
    European Urology Oncology.2022; 5(4): 403.     CrossRef
  • 12,807 View
  • 199 Download
  • 14 Web of Science
  • 13 Crossref
Close layer
Pediatric cancer
Effectiveness and Safety of Dabrafenib in the Treatment of 20 Chinese Children with BRAFV600E-Mutated Langerhans Cell Histiocytosis
Ying Yang, Dong Wang, Lei Cui, Hong-Hao Ma, Li Zhang, Hong-Yun Lian, Qing Zhang, Xiao-Xi Zhao, Li-Ping Zhang, Yun-Ze Zhao, Na Li, Tian-You Wang, Zhi-Gang Li, Rui Zhang
Cancer Res Treat. 2021;53(1):261-269.   Published online September 15, 2020
DOI: https://doi.org/10.4143/crt.2020.769
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
We sought to investigate the effectiveness and safety of dabrafenib in children with BRAFV600E-mutated Langerhans cell histiocytosis (LCH).
Materials and Methods
A retrospective analysis was performed on 20 children with BRAFV600E-mutated LCH who were treated with dabrafenib.
Results
The median age at which the patients started taking dabrafenib was 2.3 years old (range, 0.6 to 6.5 years). The ratio of boys to girls was 2.3:1. The median follow-up time was 30.8 months (range, 18.9 to 43.6 months). There were 14 patients (70%) in the risk organ (RO)+ group and six patients (30%) in the RO group. All patients were initially treated with traditional chemotherapy and then shifted to targeted therapy due to poor control of LCH or intolerance to chemotherapy. The overall objective response rate and the overall disease control rate were 65% and 75%, respectively. During treatment, circulating levels of cell-free BRAFV600E (cfBRAFV600E) became negative in 60% of the patients within a median period of 3.0 months (range, 1.0 to 9.0 months). Grade 2 or 3 adverse effects occurred in five patients.
Conclusion
Some children with BRAFV600E-mutated LCH may benefit from monotherapy with dabrafenib, especially high-risk patients with concomitant hemophagocytic lymphohistiocytosis and intolerance to chemotherapy. The safety of dabrafenib is notable. A prospective study with a larger sample size is required to determine the optimal dosage and treatment duration.

Citations

Citations to this article as recorded by  
  • Genetic Landscape and Its Prognostic Impact in Children With Langerhans Cell Histiocytosis
    Chan-Juan Wang, Lei Cui, Shuang-Shuang Li, Hong-Hao Ma, Dong Wang, Hong-Yun Lian, Yun-Ze Zhao, Li-Ping Zhang, Wei-Jing Li, Qing Zhang, Xiao-Xi Zhao, Ying Yang, Xiao-Tong Huang, Wei Liu, Yi-Zhuo Wang, Wan-Shui Wu, Tian-You Wang, Rui Zhang, Zhi-Gang Li
    Archives of Pathology & Laboratory Medicine.2025; 149(2): 175.     CrossRef
  • Targeted therapy and immunotherapy for orbital and periorbital tumors: a major review
    Emmanuel Lee Boniao, Richard C. Allen, Gangadhara Sundar
    Orbit.2024; 43(5): 656.     CrossRef
  • Treatment of children with refractory/relapse high risk langerhans cell histiocytosis with the combination of cytarabine, vindesine and prednisone
    Wenqian Wang, Jian Ge, Honghao Ma, Hongyun Lian, Lei Cui, Yunze Zhao, Zhigang Li, Tianyou Wang, Rui Zhang
    BMC Pediatrics.2024;[Epub]     CrossRef
  • Vemurafenib combined with chemotherapy achieved sustained remission in pediatric LCH: a multi-center observational study
    Jiaying Lei, Wenxia Wang, Danna Lin, Chengguang Zhu, Wenguang Jia, Wenjun Weng, Xiaoshan Liu, Yuhan Ma, Zhixuan Wang, Lihua Yang, Xiangling He, Yunyan He, Yang LI
    Journal of Cancer Research and Clinical Oncology.2024;[Epub]     CrossRef
  • Clinical features and treatment outcomes of liver involvement in paediatric Langerhans cell histiocytosis
    Xinshun Ge, Wenxin Ou, Ang Wei, Hongyun Lian, Honghao Ma, Lei Cui, Dong Wang, Liping Zhang, Xiaoman Wang, Lejian He, Rui Zhang, Tianyou Wang
    BMC Pediatrics.2024;[Epub]     CrossRef
  • Refractory juvenile xanthogranuloma of the mastoid bone responsive to trametinib
    Isaac Hauk, Ignacio Gonzalez‐Gomes, Deepak Chellapandian, Jonathan Metts, Peter H. Shaw
    Pediatric Blood & Cancer.2024;[Epub]     CrossRef
  • Advancements in the understanding and management of histiocytic neoplasms
    Kyung-Nam Koh, Su Hyun Yoon, Sung Han Kang, Hyery Kim, Ho Joon Im
    Blood Research.2024;[Epub]     CrossRef
  • Real-world experience with targeted therapy in patients with histiocytic neoplasms in the Netherlands and in Belgium
    Paul G. Kemps, F. J. Sherida H. Woei-A-Jin, Patrick Schöffski, Thomas Tousseyn, Isabelle Vanden Bempt, Friederike A. G. Meyer-Wentrup, Natasja Dors, Natasha K. A. van Eijkelenburg, Marijn A. Scheijde-Vermeulen, Ingrid M. Jazet, Maarten Limper, Margot Jak,
    Blood Neoplasia.2024; 1(3): 100023.     CrossRef
  • The clinical impact of serum soluble CD25 levels in children with Langerhans cell histiocytosis
    Zi-Jing Zhao, Hong-Yun Lian, Wei-Jing Li, Qing Zhang, Hong-Hao Ma, Dong Wang, Yun-Ze Zhao, Ting Zhu, Hua-Lin Li, Xiao-Tong Huang, Tian-You Wang, Rui Zhang, Lei Cui, Zhi-Gang Li
    Jornal de Pediatria.2024;[Epub]     CrossRef
  • Liver transplantation in a child with sclerosing cholangitis due to Langerhans cell histiocytosis: a case report
    Xue-Lian Wang, Chun-Xiao Fang, Min-Xia Chen, Hua-Mei Yang, Lan-Hui She, Yu Gong, Yi Xu, Wei-Qiang Xiao, Jin-Sheng Tian, Bin Ai, Li Huang, Xu-Fang Li
    Frontiers in Pediatrics.2024;[Epub]     CrossRef
  • BRAF V600E gene mutation is present in primary intraosseous Rosai-Dorfman disease
    Lokman Cevik, Swati Satturwar, Dan Jones, Joel Mayerson, Steve Oghumu, O. Hans Iwenofu
    Human Pathology.2024; 154: 105702.     CrossRef
  • Langerhans cell histiocytosis as a clonal disease of mononuclear phagocyte system
    Evgeniy F. Khynku, Maria K. Monaenkova, Olga B. Tamrazova, Alexey V. Taganov, Мarina А. Gureeva, Gayane E. Bagramova, Anton V. Molochkov
    Almanac of Clinical Medicine.2023; 50(7): 428.     CrossRef
  • Lineage switching of the cellular distribution of BRAF V600E in multisystem Langerhans cell histiocytosis
    Paul Milne, Simon Bomken, Olga Slater, Ashish Kumar, Adam Nelson, Somak Roy, Jessica Velazquez, Kshitij Mankad, James Nicholson, Dan Yeomanson, Richard Grundy, Ahmed Kamal, Anthony Penn, Jane Pears, Gerard Millen, Bruce Morland, James Hayden, Jason Lam, M
    Blood Advances.2023; 7(10): 2171.     CrossRef
  • Treatment of Langerhans Cell Histiocytosis and Histiocytic Disorders: A Focus on MAPK Pathway Inhibitors
    Ashley V. Geerlinks, Oussama Abla
    Pediatric Drugs.2023; 25(4): 399.     CrossRef
  • Dabrafenib, alone or in combination with trametinib, in BRAF V600–mutated pediatric Langerhans cell histiocytosis
    James A. Whitlock, Birgit Geoerger, Ira J. Dunkel, Michael Roughton, Jeea Choi, Lisa Osterloh, Mark Russo, Darren Hargrave
    Blood Advances.2023; 7(15): 3806.     CrossRef
  • Therapiestrategien bei Kindern und Jugendlichen mit Langerhanszell Histiozytosen
    Anke Elisabeth Barnbrock, Caroline Hutter, Konrad Bochennek, Milen Minkov, Thomas Lehrnbecher
    Klinische Pädiatrie.2023; 235(06): 342.     CrossRef
  • Mutant PIK3CA is a targetable driver alteration in histiocytic neoplasms
    Benjamin H. Durham, Oshrat Hershkovitz-Rokah, Omar Abdel-Wahab, Mariko Yabe, Young Rock Chung, Gilad Itchaki, Maayan Ben-Sasson, Vered A. Asher-Guz, David Groshar, Seyram A. Doe-Tetteh, Tina Alano, David B. Solit, Ofer Shpilberg, Eli L. Diamond, Roei D. M
    Blood Advances.2023; 7(23): 7319.     CrossRef
  • Validation of Liquid Chromatography Coupled with Tandem Mass Spectrometry for the Determination of 12 Tyrosine Kinase Inhibitors (TKIs) and Their Application to Therapeutic Drug Monitoring in Adult and Pediatric Populations
    Marie Bellouard, Jean Donadieu, Pauline Thiebot, Etienne Giroux Leprieur, Philippe Saiag, Isabelle Etting, Pamela Dugues, Emuri Abe, Jean-Claude Alvarez, Islam-Amine Larabi
    Pharmaceutics.2023; 16(1): 5.     CrossRef
  • Langerhans cell histiocytosis: promises and caveats of targeted therapies in high-risk and CNS disease
    Oussama Abla
    Hematology.2023; 2023(1): 386.     CrossRef
  • Characteristics and Treatment Outcomes of Pediatric Langerhans Cell Histiocytosis with Thymic Involvement
    Ja-Feng Yao, Dong Wang, Hong-Hao Ma, Hong-Yun Lian, Li Zhang, Tian-You Wang, Zhi-Gang Li, Jin Jiang, Lei Cui, Rui Zhang
    The Journal of Pediatrics.2022; 244: 194.     CrossRef
  • Clinical features and treatment outcomes of pediatric Langerhans cell histiocytosis with macrophage activation syndrome-hemophagocytic lymphohistiocytosis
    Dong Wang, Xi-Hua Chen, Ang Wei, Chun-Ju Zhou, Xue Zhang, Hong-Hao Ma, Hong-Yun Lian, Li Zhang, Qing Zhang, Xiao-Tong Huang, Chan-Juan Wang, Ying Yang, Wei Liu, Tian-You Wang, Zhi-Gang Li, Lei Cui, Rui Zhang
    Orphanet Journal of Rare Diseases.2022;[Epub]     CrossRef
  • Current perspectives on the role of liver transplantation for Langerhans cell histiocytosis: A narrative review
    Jagadeesh Menon, Ashwin Rammohan, Mukul Vij, Naresh Shanmugam, Mohamed Rela
    World Journal of Gastroenterology.2022; 28(30): 4044.     CrossRef
  • Research Progress of BRAF V600E Gene Mutation in Papillary Thyroid Carcinoma
    延泽 刘
    Advances in Clinical Medicine.2022; 12(09): 8499.     CrossRef
  • Recent advances in the understanding of the molecular pathogenesis and targeted therapy options in Langerhans cell histiocytosis
    Jin Kyung Suh, Sunghan Kang, Hyery Kim, Ho Joon Im, Kyung-Nam Koh
    BLOOD RESEARCH.2021; 56(S1): S65.     CrossRef
  • Improvement in Pituitary Imaging After Targeted Therapy in Three Children with BRAF-Mutated Langerhans Cell Histiocytosis with Pituitary Involvement


    Ying Yang, Dong Wang, Na Li, Honghao Ma, Hongyun Lian, Lei Cui, Qing Zhang, Xiaoxi Zhao, Liping Zhang, Yunze Zhao, Chanjuan Wang, Li Zhang, Tianyou Wang, Zhigang Li, Rui Zhang
    OncoTargets and Therapy.2020; Volume 13: 12357.     CrossRef
  • 34,884 View
  • 234 Download
  • 19 Web of Science
  • 25 Crossref
Close layer
BRAF-Activated Long Noncoding RNA Modulates Papillary Thyroid Carcinoma Cell Proliferation through Regulating Thyroid Stimulating Hormone Receptor
Haitao Zheng, Meng Wang, Lixin Jiang, Haidi Chu, Jinchen Hu, Jinyao Ning, Baoyuan Li, Dong Wang, Jie Xu
Cancer Res Treat. 2016;48(2):698-707.   Published online August 12, 2015
DOI: https://doi.org/10.4143/crt.2015.118
AbstractAbstract PDFPubReaderePub
Purpose
The importance of long noncoding RNAs (lncRNAs) in tumorigenesis has recently been demonstrated. However, the role of lncRNAs in development of thyroid cancer remains largely unknown. Materials and Methods Using quantitative reverse transcription polymerase chain reaction, expression of three lncRNAs, including BRAF-activated long noncoding RNA (BANCR), papillary thyroid cancer susceptibility candidate 3 (PTCSC3), and noncoding RNA associated with mitogen-activated protein kinase pathway and growth arrest (NAMA), was investigated in the current study.
Results
Of the three lncRNAs (BANCR, PTCSC3, and NAMA), expression of BANCR was significantly up-regulated while PTCSC3 and NAMA were significantly down-regulated in papillary thyroid carcinoma (PTC) compared to that in normal tissue. BANCR-knockdown in a PTC-derived cell line (IHH-4) resulted in significant suppression of thyroid stimulating hormone receptor (TSHR). BANCR-knockdown also led to inhibition of cell growth and cell cycle arrest at G0/G1 phase through down-regulation of cyclin D1. In addition, BANCR was enriched by polycomb enhancer of zeste homolog 2 (EZH2), and silencing BANCR led to decreased chromatin recruitment of EZH2, which resulted significantly reduced expression of TSHR. Conclusion These findings indicate that BANCR may contribute to the tumorigenesis of PTC through regulation of cyclin D1 and TSHR.

Citations

Citations to this article as recorded by  
  • YTHDC2 Retards Cell Proliferation and Triggers Apoptosis in Papillary Thyroid Cancer by Regulating CYLD-Mediated Inactivation of Akt Signaling
    Guangying Zhou, Shasha Wang
    Applied Biochemistry and Biotechnology.2024; 196(1): 588.     CrossRef
  • LncRNA PFAR facilitates the proliferation and migration of papillary thyroid carcinoma by competitively binding to miR-15a
    Tie Fang, Kejie Yu
    Naunyn-Schmiedeberg's Archives of Pharmacology.2024; 397(5): 3037.     CrossRef
  • The role of genetic and epigenetic modifications as potential biomarkers in the diagnosis and prognosis of thyroid cancer
    Essa M. Sabi
    Frontiers in Oncology.2024;[Epub]     CrossRef
  • A review on the biological roles of LncRNA PTCSC3 in cancerous and non-cancerous disorders
    Majid Ghasemian, Jafar Poodineh
    Cancer Cell International.2023;[Epub]     CrossRef
  • Overexpression of ST7-AS1 Enhances Apoptosis and Inhibits Proliferation of Papillary Thyroid Carcinoma Cells Via microRNA-181b-5p-Dependent Inhibition Tripartite Motif Containing 3
    Yuan Zhao, Xiaoyun Feng, Yonggang Zhao, Huijuan Yang, Chunjie Zhang
    Molecular Biotechnology.2023; 65(3): 477.     CrossRef
  • Advances and challenges in thyroid cancer: The interplay of genetic modulators, targeted therapies, and AI-driven approaches
    Srinjan Bhattacharya, Rahul Kumar Mahato, Satwinder Singh, Gurjit Kaur Bhatti, Sarabjit Singh Mastana, Jasvinder Singh Bhatti
    Life Sciences.2023; 332: 122110.     CrossRef
  • Identification of prognostic signature with seven LncRNAs for papillary thyroid carcinoma
    Chengang Guo, Huafang Li, Na Pan, Shicai Xu, Qiangcheng Zeng, Bailing Zhou, Jihua Wang
    Advances in Medical Sciences.2022; 67(1): 103.     CrossRef
  • LINC01087 Promotes the Proliferation, Migration, and Invasion of Thyroid Cancer Cells by Upregulating PPM1E
    Ying Yin, Jianhao Huang, Hongyan Shi, Yijie Huang, Ziyang Huang, Muye Song, Liping Yin, Wei long Zhong
    Journal of Oncology.2022; 2022: 1.     CrossRef
  • Knockdown of KRAB domain-associated protein 1 suppresses the proliferation, migration and invasion of thyroid cancer cells by regulating P68/DEAD box protein 5
    Hai Lan, Congyao Lin, Hongyin Yuan
    Bioengineered.2022; 13(5): 11945.     CrossRef
  • The NEAT1_2/miR-491 Axis Modulates Papillary Thyroid Cancer Invasion and Metastasis Through TGM2/NFκb/FN1 Signaling
    Wei Sun, Yuan Qin, Zhihong Wang, Wenwu Dong, Liang He, Ting Zhang, Hao Zhang
    Frontiers in Oncology.2021;[Epub]     CrossRef
  • Long noncoding RNA ILF3-AS1 aggravates papillary thyroid carcinoma progression via regulating the miR-4306/PLAGL2 axis
    Zhaohui Zeng, Qiangfeng Teng, Jinhong Xiao
    Cancer Cell International.2021;[Epub]     CrossRef
  • Role of lncRNA BANCR in Human Cancers: An Updated Review
    Bashdar Mahmud Hussen, Tahereh Azimi, Atefe Abak, Hazha Jamal Hidayat, Mohammad Taheri, Soudeh Ghafouri-Fard
    Frontiers in Cell and Developmental Biology.2021;[Epub]     CrossRef
  • Long noncoding RNA landscapes specific to benign and malignant thyroid neoplasms of distinct histological subtypes
    Valentina D. Yakushina, Vladimir V. Strelnikov, Alexander S. Tanas, Alexander V. Lavrov
    Scientific Reports.2021;[Epub]     CrossRef
  • LncRNA-MIAT promotes thyroid cancer progression and function as ceRNA to target EZH2 by sponging miR-150-5p
    Kai Guo, Kai Qian, Yuan Shi, Tuanqi Sun, Zhuoying Wang
    Cell Death & Disease.2021;[Epub]     CrossRef
  • Epigenetic modification and BRAF gene mutation in thyroid carcinoma
    Guo Huang, Juan Chen, Jun Zhou, Shuai Xiao, Weihong Zeng, Jiliang Xia, Xi Zeng
    Cancer Cell International.2021;[Epub]     CrossRef
  • MicroRNA‐384 Inhibits the Progression of Papillary Thyroid Cancer by Targeting PRKACB
    Yongxia Wang, Beixi Wang, Hong Zhou, Xiangnan Zhang, Xinlai Qian, Jing Cui, Alfredo Conti
    BioMed Research International.2020;[Epub]     CrossRef
  • The role of long non-coding RNAs in the pathogenesis of thyroid cancer
    Soudeh Ghafouri-Fard, Hossein Mohammad-Rahimi, Mohammad Taheri
    Experimental and Molecular Pathology.2020; 112: 104332.     CrossRef
  • The Role of Long Non-Coding RNAs in Thyroid Cancer
    Xuejiao Peng, Kun Zhang, Li Ma, Junfeng Xu, Weiqin Chang
    Frontiers in Oncology.2020;[Epub]     CrossRef
  • Elevated BANCR expression levels have different effects on papillary thyroid carcinoma progression depending on the presence of the BRAFV600E mutation
    Stefana Stojanović, Sonja Šelemetjev, Ilona Đorić, Jelena Rončević, Jelena Janković Miljuš, Vladan Živaljević, Tijana Išić Denčić
    European Journal of Surgical Oncology.2020; 46(10): 1835.     CrossRef
  • Chaperone-mediated Autophagy Governs Progression of Papillary Thyroid Carcinoma via PPARγ-SDF1/CXCR4 Signaling
    Hong Zhou, Xin Xie, Ying Chen, Yi Lin, Zhaogen Cai, Li Ding, Yijie Wu, Yongde Peng, Shanshan Tang, Huanbai Xu
    The Journal of Clinical Endocrinology & Metabolism.2020; 105(10): 3308.     CrossRef
  • LncRNA ENST00000539653 acts as an oncogenic factor via MAPK signalling in papillary thyroid cancer
    Bin Song, Rurun Li, Zhihua Zuo, Juan Tan, Ling Liu, Dafa Ding, Yibing Lu, Dawei Hou
    BMC Cancer.2019;[Epub]     CrossRef
  • Long noncoding RNA RP11‐547D24.1 regulates proliferation and migration in papillary thyroid carcinoma: Identification and validation of a novel long noncoding RNA through integrated analysis of TCGA database
    Kai Guo, Lili Chen, Yunjun Wang, Kai Qian, Xiaoke Zheng, Wenyu Sun, Tuanqi Sun, Yi Wu, Zhuoying Wang
    Cancer Medicine.2019; 8(6): 3105.     CrossRef
  • Molecular aberrations and signaling cascades implicated in the pathogenesis of anaplastic thyroid cancer
    Shikha Saini, Ajay V. Maker, Kenneth D. Burman, Bellur S. Prabhakar
    Biochimica et Biophysica Acta (BBA) - Reviews on Cancer.2019; 1872(2): 188262.     CrossRef
  • A novel lncRNA n384546 promotes thyroid papillary cancer progression and metastasis by acting as a competing endogenous RNA of miR-145-5p to regulate AKT3
    Jiajia Feng, Qinyi Zhou, Hongliang Yi, Shiyin Ma, Dawei Li, Yanan Xu, Jiadong Wang, Shankai Yin
    Cell Death & Disease.2019;[Epub]     CrossRef
  • Long non‐coding RNA NR2F1‐AS1 promoted proliferation and migration yet suppressed apoptosis of thyroid cancer cells through regulating miRNA‐338‐3p/CCND1axis
    Feng Guo, Qingfeng Fu, Yang Wang, Guoqing Sui
    Journal of Cellular and Molecular Medicine.2019; 23(9): 5907.     CrossRef
  • Influencers on Thyroid Cancer Onset: Molecular Genetic Basis
    Berta Luzón-Toro, Raquel Fernández, Leticia Villalba-Benito, Ana Torroglosa, Guillermo Antiñolo, Salud Borrego
    Genes.2019; 10(11): 913.     CrossRef
  • Long noncoding RNAs in thyroid cancer
    Mahsa Sedaghati, Electron Kebebew
    Current Opinion in Endocrinology, Diabetes & Obesity.2019; 26(5): 275.     CrossRef
  • LINC01410/miR-3619-5p/FOXM1Feedback Loop Regulates Papillary Thyroid Carcinoma Cell Proliferation and Apoptosis
    Gang Wang, Xin Wang, Ying Jin
    Cancer Biotherapy and Radiopharmaceuticals.2019; 34(9): 572.     CrossRef
  • LncRNAs SNHG12 and LINC00152 were Associated with Progression of Patients with Papillary Thyroid Carcinoma
    Jianqiu Liu, Xinyue Tang, Jing Lv, Xiaowei Peng, Ke Zhang, Cuilin Li, Jie Liu, Guo Wang, Zhi Li
    Future Oncology.2019; 15(36): 4167.     CrossRef
  • Long non‑coding RNA H19 knockdown inhibits the cell viability and promotes apoptosis of thyroid cancer cells through regulating the PI3K/AKT pathway
    Xiaoyu Li, Qinghuai Li, Xiao Jin, Hao Guo, Yong Li
    Experimental and Therapeutic Medicine.2019;[Epub]     CrossRef
  • Oncogenic Properties of the Antisense lncRNA COMET in BRAF- and RET-Driven Papillary Thyroid Carcinomas
    Roberta Esposito, Daniela Esposito, Pierlorenzo Pallante, Alfredo Fusco, Alfredo Ciccodicola, Valerio Costa
    Cancer Research.2019; 79(9): 2124.     CrossRef
  • Long non-coding RNAs in thyroid cancer: Biological functions and clinical significance
    Fang Sui, Meiju Ji, Peng Hou
    Molecular and Cellular Endocrinology.2018; 469: 11.     CrossRef
  • Periostin silencing suppresses the aggressive phenotype of thyroid carcinoma cells by suppressing the Akt/thyroid stimulating hormone receptor axis
    Min Wang, Chunyi Gui, Shenglong Qiu, Jingdong Tang, Zhihai Peng
    Cytotechnology.2018; 70(1): 275.     CrossRef
  • Long noncoding RNAs: emerging players in thyroid cancer pathogenesis
    Avaniyapuram Kannan Murugan, Arasambattu Kannan Munirajan, Ali S Alzahrani
    Endocrine-Related Cancer.2018; 25(2): R59.     CrossRef
  • The BRAF activated non‐coding RNA: A pivotal long non‐coding RNA in human malignancies
    Xiu‐Fen Liu, Ji‐Long Hao, Tian Xie, Om Prakash Pant, Cheng‐Bo Lu, Cheng‐Wei Lu, Dan‐Dan Zhou
    Cell Proliferation.2018;[Epub]     CrossRef
  • RETRACTED: Long noncoding RNA PVT1 enhances the viability and invasion of papillary thyroid carcinoma cells by functioning as ceRNA of microRNA-30a through mediating expression of insulin like growth factor 1 receptor
    Kun Feng, Yu Liu, Li-Juan Xu, Ling-Fei Zhao, Chao-Wen Jia, Ming-Yan Xu
    Biomedicine & Pharmacotherapy.2018; 104: 686.     CrossRef
  • LncRNA BISPR promotes the progression of thyroid papillary carcinoma by regulating miR-21-5p
    Hong Zhang, Yuechang Cai, Li Zheng, Zhanlei Zhang, Xiaofeng Lin, Ningyi Jiang
    International Journal of Immunopathology and Pharmacology.2018;[Epub]     CrossRef
  • LncRNA TNRC6C‐AS1 regulates UNC5B in thyroid cancer to influence cell proliferation, migration, and invasion as a competing endogenous RNA of miR‐129‐5p
    Sen Hou, Qiuyu Lin, Feng Guan, Chenghe Lin
    Journal of Cellular Biochemistry.2018; 119(10): 8304.     CrossRef
  • CircRNA circRNA_102171 promotes papillary thyroid cancer progression through modulating CTNNBIP1-dependent activation of β-catenin pathway
    Wen Bi, Jiayu Huang, Chunlei Nie, Bo Liu, Guoqing He, Jihua Han, Rui Pang, Zhaoming Ding, Jin Xu, Jiewu Zhang
    Journal of Experimental & Clinical Cancer Research.2018;[Epub]     CrossRef
  • Current research on head and neck cancer-associated long noncoding RNAs
    Wei Song, Yimin Sun, Jie Lin, Xiaoqin Bi
    Oncotarget.2018; 9(1): 1403.     CrossRef
  • lncRNA BANCR promotes EMT in PTC via the Raf/MEK/ERK signaling pathway
    Yuanyuan Wang, Jiaojiao Gu, Xiangde Lin, Wei Yan, Wenchao Yang, Guoyang Wu
    Oncology Letters.2018;[Epub]     CrossRef
  • Expression of BANCR promotes papillary thyroid cancer by targeting thyroid stimulating hormone receptor
    Haitao Zheng, Jie Xu, Shaolong Hao, Xincheng Liu, Jinrao Ning, Xicheng Song, Lixin Jiang, Zongying Liu
    Oncology Letters.2018;[Epub]     CrossRef
  • Epigenetic modulators of thyroid cancer
    Sandra Rodríguez-Rodero, Elías Delgado-Álvarez, Lucía Díaz-Naya, Alicia Martín Nieto, Edelmiro Menéndez Torre
    Endocrinología, Diabetes y Nutrición.2017; 64(1): 44.     CrossRef
  • Epigenetic modulators of thyroid cancer
    Sandra Rodríguez-Rodero, Elías Delgado-Álvarez, Lucía Díaz-Naya, Alicia Martín Nieto, Edelmiro Menéndez Torre
    Endocrinología, Diabetes y Nutrición (English ed.).2017; 64(1): 44.     CrossRef
  • Identification of Long Noncoding RNAs Deregulated in Papillary Thyroid Cancer and Correlated with BRAFV600E Mutation by Bioinformatics Integrative Analysis
    Lucas Goedert, Jessica Rodrigues Plaça, Cesar Seigi Fuziwara, Maiaro Cabral Rosa Machado, Desirée Rodrigues Plaça, Palloma Porto Almeida, Talita Perez Sanches, Jair Figueredo dos Santos, Amanda Cristina Corveloni, Illy Enne Gomes Pereira, Marcela Motta de
    Scientific Reports.2017;[Epub]     CrossRef
  • Comprehensive analysis of long noncoding RNA–mRNA co-expression patterns in thyroid cancer
    Yaying Du, Wenfei Xia, Jinjun Zhang, Dongyi Wan, Zhifang Yang, Xingrui Li
    Molecular BioSystems.2017; 13(10): 2107.     CrossRef
  • Long non-coding RNAs act as regulators of cell autophagy in diseases
    Zhijie Xu, Yuanliang Yan, Long Qian, Zhicheng Gong
    Oncology Reports.2017; 37(3): 1359.     CrossRef
  • Prognostic Role of Long Noncoding RNA BANCR in Solid Tumors: A Meta-Analysis
    Jun Zhao, Yali Qi, Jiahao Hu, Wenwen Dai, Yifei Chen
    Technology in Cancer Research & Treatment.2017; 16(6): 727.     CrossRef
  • MicroRNA-150 targets Rho-associated protein kinase 1 to inhibit cell proliferation, migration and invasion in papillary thyroid carcinoma
    Lixia Cheng, Ruixiu Zhou, Min Chen, Linan Feng, Hongyan Li
    Molecular Medicine Reports.2017; 16(2): 2217.     CrossRef
  • Downregulation of BRAF-activated non-coding RNA suppresses the proliferation, migration and invasion, and induces apoptosis of hepatocellular carcinoma cells
    Jing Li, Jinfeng Wang, Wei Zhou, Shuqin Zhang, Yuan Le, Rong He
    Oncology Letters.2017; 14(4): 4751.     CrossRef
  • MALAT1 Long Non-coding RNA Expression in Thyroid Tissues: Analysis by In Situ Hybridization and Real-Time PCR
    Ranran Zhang, Heather Hardin, Wei Huang, Jidong Chen, Sofia Asioli, Alberto Righi, Francesca Maletta, Anna Sapino, Ricardo V. Lloyd
    Endocrine Pathology.2017; 28(1): 7.     CrossRef
  • BRAF-activated LncRNA functions as a tumor suppressor in papillary thyroid cancer
    Tian Liao, Ning Qu, Rong-Liang Shi, Kai Guo, Ben Ma, Yi-Ming Cao, Jun Xiang, Zhong-Wu Lu, Yong-Xue Zhu, Duan-Shu Li, Qing-Hai Ji
    Oncotarget.2017; 8(1): 238.     CrossRef
  • MicroRNA‑335 is downregulated in papillary thyroid cancer and suppresses cancer cell growth, migration and invasion by directly targeting ZEB2
    Quan'e Kan, Yong Su, Huihui Yang
    Oncology Letters.2017;[Epub]     CrossRef
  • 14,385 View
  • 163 Download
  • 61 Web of Science
  • 53 Crossref
Close layer

Cancer Res Treat : Cancer Research and Treatment
Close layer
TOP